Keflex

References

1. IMS Health, National Prescription Audit, Retail Channels.

2. Keflex^® Prescribing Information. Germantown, MD: MiddleBrook Pharmaceuticals, Inc.; 2007.

3. Leibovitz E. Acute otitis media in pediatric medicine: current issues in epidemiology, diagnosis, and management. Pediatr Drugs. 2003;(5 suppl 1):
1-12.

4. Ofili EO. Dispelling the myth of “aggressive” antihypertensive therapy. J Clin Hypertens. 2006;8(1 suppl 1):4-11.

5. Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother. 2002;49:897-903.

6. NOP World Health Market Research, March 26, 2004.

7. Schwartz HI, Perschy TB, McSorley DJ, Sorrells SC. Twice-daily versus thrice-daily clarithromycin in combination with ranitidine bismuth citrate in the eradication of Helicobacter pylori. Helicobacter. 1999;4:121-127.

KEFLEX is indicated for the treatment of respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections in adults and children six months and older.

Important Safety Information
KEFLEX is contraindicated in patients with known allergy to the cephalosporin group of antibiotics. Before therapy with cephalexin is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cephalexin, cephalosporins, penicillins, or other drugs. KEFLEX should be administered with caution in the presence of markedly impaired renal function or a history of gastrointestinal disease, particularly Clostridium difficile associated diarrhea (CDAD).

904-0606-0017r

MiddleBrook Pharmaceuticals, Inc.